We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.
- Recent NEO Stock Price: $18.25
- Yearly Gain for NEO stock: 88.26%
- Market Cap for NEO stock: $1.95B
- P/E Ratio for NEO stock: -13.249
Will NEO's stock price go up? Is there an accurate NEO stock forecast available?
TipRanks.com reports that NeoGenomics currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $20.78. The target pricing ranges from a high NEO forecast of $25.00 down to a low forecast of $17.00. NeoGenomics (NEO)’s last closing stock price was $18.25 which would put the average price target at 13.86% upside.
In addition, TradingView issued a Strong Buy rating for NEO stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on NEO stock.
Other analysts covering NEO include:
- David Westenberg of Piper Sandler issued a Buy rating with the price target of $ 20 on 22 hours ago
- Daniel Brennan of TD Cowen issued a Buy rating with the price target of $ 22 on 22 hours ago
- Matthew Sykes of Goldman Sachs issued a Buy rating with the price target of $ 19 on 22 hours ago
If you are wondering if NEO is a good stock to buy, here are 3rd party ratings for NEO stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 36% (90 out of 250)
What is the sentiment on the street regarding NeoGenomics? (Current ratings compiled by TipRanks.com)
- News Sentiment for NEO stock: Very Bullish
- Blogger Consensus for NEO stock: Bullish
- Media Buzz for NEO stock: Low
- Insider Signal for NEO stock: ―
- Investor Sentiment for NEO stock: Negative
- Hedge Fund signal for NEO stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on NEO stock including scouring the social networks like NEO StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for NEO stock chart >>
Summary: McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions.
- Recent MCK Stock Price: $388.72
- Yearly Gain for MCK stock: 12.40%
- Market Cap for MCK stock: $50.10B
- P/E Ratio for MCK stock: 16.899
Will MCK's stock price go up? Is there an accurate MCK stock forecast available?
TipRanks.com reports that McKesson currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $445.33. The target pricing ranges from a high MCK forecast of $491.00 down to a low forecast of $390.00. McKesson (MCK)’s last closing stock price was $388.72 which would put the average price target at 14.56% upside.
In addition, TradingView issued a Strong Buy rating for MCK stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MCK stock.
Other analysts covering MCK include:
- Charles Rhyee of TD Cowen issued a Buy rating with the price target of $ 491 on 22 hours ago
- Eric Coldwell of Robert W. Baird issued a Buy rating with the price target of $ 475 on 22 hours ago
- Kevin Caliendo of UBS issued a Buy rating with the price target of $ 450 on 22 hours ago
- Steven Valiquette of Barclays issued a Buy rating with the price target of $ 420 on 22 hours ago
If you are wondering if MCK is a good stock to buy, here are 3rd party ratings for MCK stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 18% (46 out of 250)
What is the sentiment on the street regarding McKesson? (Current ratings compiled by TipRanks.com)
- News Sentiment for MCK stock: Very Bullish
- Blogger Consensus for MCK stock: Bullish
- Media Buzz for MCK stock: Medium
- Insider Signal for MCK stock: ―
- Investor Sentiment for MCK stock: Negative
- Hedge Fund signal for MCK stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on MCK stock including scouring the social networks like MCK StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MCK stock chart >>
Summary: Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as'dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.
- Recent ACAD Stock Price: $21.43
- Yearly Gain for ACAD stock: 31.56%
- Market Cap for ACAD stock: $3.56B
- P/E Ratio for ACAD stock: -16.116
Will ACAD's stock price go up? Is there an accurate ACAD stock forecast available?
TipRanks.com reports that ACADIA Pharmaceuticals currently has 19 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $22.92. The target pricing ranges from a high ACAD forecast of $33.00 down to a low forecast of $15.00. ACADIA Pharmaceuticals (ACAD)’s last closing stock price was $21.43 which would put the average price target at 6.95% upside.
In addition, TradingView issued a Buy rating for ACAD stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ACAD stock.
Other analysts covering ACAD include:
- Uy Ear of Mizuho Securities issued a Hold rating with the price target of $ 20 on 22 hours ago
- Andrew Fein of H.C. Wainwright issued a Buy rating with the price target of $ 28 on 22 hours ago
- Neena Bitritto-Garg of Citigroup issued a Hold rating with the price target of $ 21.6 on 22 hours ago
- Jason Butler of JMP Securities issued a Buy rating with the price target of $ 23 on 22 hours ago
If you are wondering if ACAD is a good stock to buy, here are 3rd party ratings for ACAD stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 36% (90 out of 250)
What is the sentiment on the street regarding ACADIA Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for ACAD stock: Very Bullish
- Blogger Consensus for ACAD stock: Bullish
- Media Buzz for ACAD stock: Low
- Insider Signal for ACAD stock: ―
- Investor Sentiment for ACAD stock: Very Positive
- Hedge Fund signal for ACAD stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on ACAD stock including scouring the social networks like ACAD StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ACAD stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
